Literature DB >> 31950017

A case report and review of the literature: cardiotoxicities after radiotherapy for breast cancer patients with high-risk factors of cardiovascular disease.

Liuwei Tang1, Haruo Matsushita1, Yojiro Ishikawa1, Takanori Ishida2, Keiichi Jingu1.   

Abstract

Cardiovascular disease (CVD) is an important adverse effect of radiotherapy and is responsible for increased morbidity and mortality in long-term survivors with breast cancer. Patients may have pre-existing cardiovascular risk factors before treatment of breast cancer, and the effects of pre-existing cardiovascular risk factors can be compounded by radiotherapy. We report a case of left breast cancer in a 63-year-old female with a high risk of CVD who was suspected of having radiation-induced myocardium injury 1 year after postoperative adjuvant therapy. Radiation oncologists should not only reduce the adverse effects by perfecting radiotherapy technology but also consider reducing other high-risk factors for CVD. © The Japan Society of Clinical Oncology 2019.

Entities:  

Keywords:  Breast cancer; Cardiovascular disease; Radiotherapy

Year:  2019        PMID: 31950017      PMCID: PMC6942553          DOI: 10.1007/s13691-019-00390-6

Source DB:  PubMed          Journal:  Int Cancer Conf J        ISSN: 2192-3183


  19 in total

1.  Meta-analysis of cohort studies of baseline prehypertension and risk of coronary heart disease.

Authors:  Li Shen; Hong Ma; Mei-Xiang Xiang; Jian-An Wang
Journal:  Am J Cardiol       Date:  2013-04-19       Impact factor: 2.778

2.  Cardiovascular complications of diabetes.

Authors:  David C W Lau; Garry X Shen
Journal:  Can J Diabetes       Date:  2013-10       Impact factor: 4.190

Review 3.  Molecular mechanism involved in cyclophosphamide-induced cardiotoxicity: Old drug with a new vision.

Authors:  Ashif Iqubal; Mohammad Kashif Iqubal; Sumit Sharma; Mohd Asif Ansari; Abul Kalam Najmi; Syed Mansoor Ali; Javed Ali; Syed Ehtaishamul Haque
Journal:  Life Sci       Date:  2018-12-12       Impact factor: 5.037

Review 4.  Cancer drugs and the heart: importance and management.

Authors:  Thomas M Suter; Michael S Ewer
Journal:  Eur Heart J       Date:  2012-07-12       Impact factor: 29.983

Review 5.  Breast cancer therapy-associated cardiovascular disease.

Authors:  Timothy M Zagar; Daniela M Cardinale; Lawrence B Marks
Journal:  Nat Rev Clin Oncol       Date:  2015-11-24       Impact factor: 66.675

6.  The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial.

Authors:  Evandro de Azambuja; Worta McCaskill-Stevens; Prudence Francis; Emmanuel Quinaux; John P A Crown; Malou Vicente; Rosa Giuliani; Bo Nordenskjöld; Jorge Gutiérez; Michael Andersson; Mireia Margeli Vila; Raimund Jakesz; Jan Demol; Joanna Dewar; Armando Santoro; Ana Lluch; Steven Olsen; Richard D Gelber; Angelo Di Leo; Martine Piccart-Gebhart
Journal:  Breast Cancer Res Treat       Date:  2010-01       Impact factor: 4.872

7.  Obesity and the risk of heart failure.

Authors:  Satish Kenchaiah; Jane C Evans; Daniel Levy; Peter W F Wilson; Emelia J Benjamin; Martin G Larson; William B Kannel; Ramachandran S Vasan
Journal:  N Engl J Med       Date:  2002-08-01       Impact factor: 91.245

Review 8.  Cardiovascular changes during chronic hypertensive states.

Authors:  Dorota Drozdz; Kalina Kawecka-Jaszcz
Journal:  Pediatr Nephrol       Date:  2013-09-12       Impact factor: 3.714

9.  Controversial issues in radiotherapy after breast-conserving surgery for early breast cancer in older patients: a systematic review.

Authors:  Liuwei Tang; Haruo Matsushita; Keiichi Jingu
Journal:  J Radiat Res       Date:  2018-11-01       Impact factor: 2.724

10.  Omentin protects H9c2 cells against docetaxel cardiotoxicity.

Authors:  Ricardo Lage; María Cebro-Márquez; Moisés Rodríguez-Mañero; José Ramón González-Juanatey; Isabel Moscoso
Journal:  PLoS One       Date:  2019-02-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.